AU5204799A - Compounds for inhibiting beta-amyloid peptide release and/or its synthesis - Google Patents

Compounds for inhibiting beta-amyloid peptide release and/or its synthesis

Info

Publication number: AU5204799A
Authority: AU; Australia
Prior art keywords: synthesis; compounds; amyloid peptide; peptide release; inhibiting beta
Prior art date: 1998-06-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU52047/99A

Inventor

James E Audia

Thomas C. Britton

George W. Huffman

Lee H. Latimer

Warren J. Porter

Richard C. Thompson

Stephen C. Wilkie

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Elan Pharmaceuticals LLC

Eli Lilly and Co

Original Assignee

Elan Pharmaceuticals LLC

Eli Lilly and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-22

Filing date

1999-06-21

Publication date

2000-01-10

1999-06-21 Application filed by Elan Pharmaceuticals LLC, Eli Lilly and Co filed Critical Elan Pharmaceuticals LLC

2000-01-10 Publication of AU5204799A publication Critical patent/AU5204799A/en

Status Abandoned legal-status Critical Current

Links

DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title 1
230000015572 biosynthetic process Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
238000003786 synthesis reaction Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

AU52047/99A 1998-06-22 1999-06-21 Compounds for inhibiting beta-amyloid peptide release and/or its synthesis Abandoned AU5204799A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10272898A	1998-06-22	1998-06-22
US09102728		1998-06-22
PCT/US1999/014007 WO1999067220A1 (en)	1998-06-22	1999-06-21	Compounds for inhibiting beta-amyloid peptide release and/or its synthesis

Publications (1)

Publication Number	Publication Date
AU5204799A true AU5204799A (en)	2000-01-10

Family

ID=22291387

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU52047/99A Abandoned AU5204799A (en)	1998-06-22	1999-06-21	Compounds for inhibiting beta-amyloid peptide release and/or its synthesis

Country Status (5)

Country	Link
EP (1)	EP1089981A1 (en)
JP (1)	JP2002518482A (en)
AU (1)	AU5204799A (en)
CA (1)	CA2325388A1 (en)
WO (1)	WO1999067220A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP990246A2 (en)	1998-08-07	2000-06-30	Du Pont Pharm Co	Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ509241A (en)	1998-08-07	2003-08-29	Du Pont Pharm Co	Succinoylamino lactams as inhibitors of alpha-beta protein production
US6737038B1 (en)	1998-11-12	2004-05-18	Bristol-Myers Squibb Company	Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
IL142816A0 (en)	1998-12-24	2002-03-10	Du Pont Pharm Co	SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
US6960576B2 (en)	1999-09-13	2005-11-01	Bristol-Myers Squibb Pharma Company	Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
US6503902B2 (en)	1999-09-13	2003-01-07	Bristol-Myers Squibb Pharma Company	Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
WO2001027108A1 (en)	1999-10-08	2001-04-19	Bristol-Myers Squibb Pharma Company	AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
US6525044B2 (en)	2000-02-17	2003-02-25	Bristol-Myers Squibb Company	Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production
EP1268433A1 (en)	2000-04-03	2003-01-02	Bristol-Myers Squibb Pharma Company	Cyclic lactams as inhibitors of a-beta-protein production
BR0110051A (en)	2000-04-03	2004-12-07	Bristol Myers Squibb Pharma Co	Compound, Compound Use, Pharmaceutical Composition and Method of Treatment of Alzheimer's Disease
US6632812B2 (en)	2000-04-11	2003-10-14	Dupont Pharmaceuticals Company	Substituted lactams as inhibitors of Aβ protein production
AU2001261728A1 (en)	2000-05-17	2001-11-26	Bristol-Myers Squibb Pharma Company	Use of small molecule radioligands for diagnostic imaging
WO2001092235A1 (en)	2000-06-01	2001-12-06	Bristol-Myers Squibb Pharma Company	LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
US6432944B1 (en)	2000-07-06	2002-08-13	Bristol-Myers Squibb Company	Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
TW200502221A (en) *	2002-10-03	2005-01-16	Astrazeneca Ab	Novel lactams and uses thereof
JP2008528448A (en)	2005-01-03	2008-07-31	ザリージェンツオブザユニバーシティオブミシガン	Compositions and methods relating to novel compounds and targets thereof
NZ568254A (en) *	2005-11-01	2011-06-30	Univ Michigan	1,4-Benzodiazepine-2,5-diones for regulating cell death and treating autoimmune diseases
CN101284828B (en) *	2007-04-12	2011-04-27	中国科学院上海药物研究所	Cycloheptanepyridine compounds, their preparation method, use and pharmaceutical composition containing such compounds
EP2398781A1 (en) *	2009-02-17	2011-12-28	Msd K.K.	1,4-benzodiazepin-2-on derivatives
AU2010322286B2 (en)	2009-11-17	2014-06-05	The Regents Of The University Of Michigan	1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ334950A (en) *	1996-11-22	2001-03-30	Lilly Co Eli	N-(aryl/heteroarylacetyl) amino acid esters and pharmaceutical compositions comprising same; useful for inhibiting beta-amyloid peptide release and/or its synthesis
AU729133B2 (en) *	1996-11-22	2001-01-25	Elan Pharmaceuticals, Inc.	N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds

1999
- 1999-06-21 EP EP99937164A patent/EP1089981A1/en not_active Withdrawn
- 1999-06-21 WO PCT/US1999/014007 patent/WO1999067220A1/en not_active Ceased
- 1999-06-21 JP JP2000555874A patent/JP2002518482A/en not_active Withdrawn
- 1999-06-21 CA CA002325388A patent/CA2325388A1/en not_active Abandoned
- 1999-06-21 AU AU52047/99A patent/AU5204799A/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2325388A1 (en)	1999-12-29
EP1089981A1 (en)	2001-04-11
WO1999067220A1 (en)	1999-12-29
JP2002518482A (en)	2002-06-25

Publication	Publication Date	Title
AU4710199A (en)	2000-01-10	Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
AU4707999A (en)	2000-01-10	Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
IL129083A0 (en)	2000-02-17	Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis
AU5204799A (en)	2000-01-10	Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
AU1831597A (en)	1997-08-11	Methods and compositions for inhibiting hexokinase
AU3300599A (en)	1999-09-15	Per-method designation of security requirements
AU4133701A (en)	2001-06-06	Methods and compositions for peptide synthesis
AU4705697A (en)	1998-04-17	Systems and methods for the synthesis of organic compounds
AU5100599A (en)	2000-02-01	Egf-genistein for prevention of restenosis
AU5602798A (en)	1998-07-17	Release composition
AU2998099A (en)	1999-09-27	Face synthesis system and methodology
AU3741699A (en)	1999-11-16	Personal location system
AU4198299A (en)	1999-12-06	Compounds and uses thereof
AU2243797A (en)	1997-08-11	Methods and compositions for inhibiting hexokinase
AU7604098A (en)	1998-12-30	Peptide compositions for tumor inhibition
AU6144099A (en)	2000-05-08	Decorative casket cover system
AU1569501A (en)	2001-06-06	Beta-aminoacid compounds useful for inhibiting beta-amyloid peptide release and/or its synthesis
EG24463A (en)	2009-07-16	Modified release pharmaceutical composition
AUPP433398A0 (en)	1998-07-16	Compounds and processes
AU1830700A (en)	2000-07-12	Quick release and fastening cover
AU3804299A (en)	1999-11-23	Closure system
AU2026801A (en)	2001-06-18	Melanin synthesis inhibition compound and composition containing the same
AU2333099A (en)	1999-10-18	Aryloxyanilides and related compounds
AU1569401A (en)	2001-06-06	Beta-aminoacid compounds useful for inhibiting beta-amyloid peptide release and/or its synthesis
AU6553998A (en)	1998-09-29	Methods for inhibiting bacterial cytotoxicity

Legal Events

Date	Code	Title	Description
2001-03-15	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase